The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis (Q27852988)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis	scientific article

Statements

scholarly article

1 reference

13 November 2016

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis (English)

1 reference

13 November 2016

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Christina Therkildsen

object named as

Christina Therkildsen

1

0 references

Troels K Bergmann

object named as

Troels K Bergmann

2

0 references

object named as

Steen Ladelund

4

0 references

object named as

Mef Nilbert

5

0 references

author name string

Tine Henrichsen-Schnack

3

0 references

publication date

July 2014

0 references

Acta Oncologica

0 references

53

0 references

852-64

0 references

7

0 references

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.3109/0284186X.2014.895036

21 April 2017

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.3109/0284186X.2014.895036

21 April 2017

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

1 reference

https://api.crossref.org/works/10.3109/0284186X.2014.895036

21 April 2017

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.3109/0284186X.2014.895036

21 April 2017

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

1 reference

https://api.crossref.org/works/10.3109/0284186X.2014.895036

21 April 2017

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

1 reference

https://api.crossref.org/works/10.3109/0284186X.2014.895036

21 April 2017

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 April 2017

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 April 2017

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 April 2017

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 April 2017

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Genomic and biological characterization of exon 4 KRAS mutations in human cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Wild-Type KRAS and BRAF Could Predict Response to Cetuximab in Chinese Colorectal Cancer Patients

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Ras proteins: different signals from different locations

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Identifiers

10.3109/0284186X.2014.895036

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852988&oldid=1500962527"